جستجوی مقالات مرتبط با کلیدواژه « Rosuvastatin » در نشریات گروه « پزشکی »
-
Objective
Rosuvastatin (RSV) is a hydrophilic, effective statin with a long half-life that stimulates bone regeneration. The present study aims to develop a new scaffold and controlled release system for RSV with favourable properties for bone tissue engineering (BTE).
Materials and MethodsIn this experimental study, high porous polycaprolactone (PCL)-gelatin scaffolds that contained different concentrations of RSV (0 mg/10 ml, 0.1 mg/10 ml, 0.5 mg/10 ml, 2.5 mg/10 ml, 12.5 mg/10 ml, and 62.5 mg/10 ml) were fabricated by the thermally-induced phase separation (TIPS) method. Mechanical and biological properties of the scaffolds were evaluated by Fourier transform infrared spectroscopy (FTIR), scanning electron microscope (SEM), compressive strength, porosity, MTT, alkaline phosphatase (ALP) activity, water contact angle, degradation rate, pH alteration, blood clotting index (BCI), and hemocompatibility.
ResultsSEM analysis confirmed that the porous structure of the scaffolds contained interconnected pores. FTIR results showed that the RSV structure was maintained during the scaffold's fabrication. RSV (up to 62.5 mg/10 ml) increased compressive strength (16.342 ± 1.79 MPa), wettability (70.2), and degradation rate of the scaffolds. Scaffolds that contained 2.5 mg/10 ml RSV had the best effect on the human umbilical cord mesenchymal stem cell (HUC-MSCs) survival, hemocompatibility, and BCI. As a sustained release system, only 31.68 ± 0.1% of RSV was released from the PCL-Gelatin-2.5 mg/10 ml RSV scaffold over 30 days. In addition, the results of ALP activity showed that RSV increased the osteogenic differentiation potential of the scaffolds.
ConclusionPCL-Gelatin-2.5 mg/10 ml RSV scaffolds have favorable mechanical, physical, and osteogenic properties for bone tissue and provide a favorable release system for RSV. They can mentioned as a a promising strategy for bone regeneration that should be further assessed in animals and clinical studies.
Keywords: Bone, Gelatin, Polycaprolactone, Regeneration, Rosuvastatin} -
سابقه و هدف
بیماری آلزایمر نوعی اختلال تخریب عصبی است که با تجمع پلاک های آمیلوییدی در نورونها همراه است. افزایش کلسترول خون باعث افزایش رسوب این پروتیین ها و تحلیل حافظه می شود. مطالعه حاضر با هدف بررسی اثر رزوواستاتین به عنوان داروی کاهنده کلسترول در رتهای آلزایمری، انجام پذیرفت.
مواد و روش هادر این مطالعه پژوهشی اصیل(تجربی)، حیوانات به گروه های کنترل، استرپتوزوتوسین (جهت القاء آلزایمر)، رزوواستاتین و رزوواستاتین همراه با استرپتوزوتوسین تقسیم شدند. در همه گروه ها سالین (μg/rat 1) و یا استرپتوزوتوسین (mg/kg 3) به صورت درون بطن مغزی تزریق شد. گاواژ سالین (ml/kg 1) یا رزوواستاتین (mg/kg 20 و 10) روزانه از یک روز قبل از کانول گذاری شروع و به مدت دو هفته ادامه یافت. در پایان دورهی تیمار آزمون اجتنابی غیرفعال، تعداد نورون های سالم در ناحیه CA1 و اندازهگیری شاخصهای استرس اکسیداتیو در سرم خون انجام شد.
یافته هااسترپتوزوتوسین در مقایسه با گروه کنترل بهطور معنیداری بازخوانی حافظه، تعداد نورونهای سالم در ناحیه CA1، قدرت آنتیاکسیدانتی کل و سطح آنزیم سوپراکسید دیسموتاز را کاهش و میزان مالوندیآلدهید را افزایش داد (0/001P<). گاواژ رزوواستاتین (mg/kg 20) به مدت 2 هفته شاخصهای فوق را در گروه استرپتوزوتوسین بهطور معنیداری معکوس کرد (0/001P<) که به معنی بهبود حافظه می باشد. گاواژ رزوواستاتین به تنهایی تاثیر معنیداری بر شاخصهای فوق نداشت (0/05<p).< span=""></p).<>
استنتاجاسترپتوزوتوسین از طریق مکانیسمهای مختلف از جمله افزایش استرس اکسیداتیو و به دنبال آن مرگ سلولی منجر به کاهش نورونهای ناحیه CA1 و کاهش حافظه میشود. به نظر می رسد رزوواستاتین قادر است از طریق مهار شاخصهای استرس اکسیداتیو از اثرات مخرب استرپتوزوتوسین بر حافظه و یادگیری جلوگیری نماید.
کلید واژگان: استرپتوزوتوسین, استرس اکسیداتیو, حافظه, رزوواستاتین, نورون های ناحیه CA1}Background and
purposeAlzheimer's disease is a neurodegenerative disorder associated with the accumulation of amyloid plaques in neurons. Increase in blood cholesterol leads to an increase in the deposition of these proteins in neurons and results in memory degradation. In the present study, the effect of rosuvastatin as a cholesterol-lowering drug was investigated in Alzheimer's rats.
Materials and methodsAnimals were divided into four groups: control, streptozotocin (to induce Alzheimer's), rosuvastatin, and rosuvastatin with streptozotocin. In intracerebroventricular injection, the groups received saline (1 μg/rat) or streptozotocin (3 mg/kg). Daily gavage of saline (1 mg/kg) or rosuvastatin (10, 20 mg/kg) started one day before cannulation and continued for two weeks. At the end of the treatment period, the rats' memory, number of healthy neurons in CA1 area, and serum oxidative stress indices were measured.
ResultsIntraventricular injection of streptozotocin significantly decreased memory recall, the number of intact neurons in CA1 area, total antioxidant power, and superoxide dismutase enzyme level; and increased serum malondialdehyde levels compared to the control group (P<0.001). In the group receiving rosuvastatin (20 mg/kg), the above indexes were significantly reversed compared to the streptozotocin group (P<0.001), which means improved memory. In rosuvastatin groups (10 and 20 mg/kg) alone, there was no significant difference in the above indexes compared to the control group (P>0.05).
ConclusionStreptozotocin leads to cell death in the CA1 region and memory dysfunction through various mechanisms such as increasing oxidative stress. It seems that rosuvastatin is able to prevent the destructive effects of streptozotocin on memory and learning by inhibiting oxidative stress indicators.
Keywords: streptozotocin, oxidative stress, memory, rosuvastatin, hippocampal CA1 neurons} -
Journal of Advances in Medical and Biomedical Research, Volume:31 Issue: 145, Mar-Apr 2023, PP 109 -116Background and Objective
Vascular stenosis is one of the causes of cardiovascular diseases (CVDs). Implementing appropriate therapeutic measures for CVDs requires preventing the progression of stenosis. The purpose of this study was to evaluate the efficacy of atorvastatin and rosuvastatin on the levels of alpha and beta apolipoproteins using systematic review and meta-analysis.
Materials and MethodsThis review was performed based on the PRISMA protocol. The ISI, Cochrane Library, Google Scholar, PubMed, and Scopus databases were independently searched by two researchers. MeSH keywords were used to recruit related articles published between 2005 and 2018. Meta-analysis was conducted in STATA 11.1software.
ResultsA total of 65 articles were found. Out of these, nine studies were ultimately included in meta-analysis. The findings showed that alpha lipoprotein level increased by 4.24 mg/dl (95% CI: -0.03; -8.45) and 8.71 mg/dl (95% CI: -1.95; -15.48) in patients treated with atorvastatin and rosuvastatin, respectively. Also, patients treated with either atorvastatin or rosuvastatin showed 40.55mg/dl (95% CI: 32.16; 45.93) and 44.78 g/dl (95% CI: 34.16; 55.39) decreases in beta-lipoprotein levels, respectively.
ConclusionAccording to the results, rosuvastatin is more effective than atorvastatin in reducing alpha apolipoprotein and increasing beta apolipoprotein levels within a short period of time.
Keywords: Atorvastatin, Rosuvastatin, Alphaapolipoprotein, Beta apolipoprotein, Systematic review, Meta-analysis} -
BackgroundNatural killer (NK) cells are dichotomously involved in chronic hepatitis B (CHB) infection as principal members of innate immunity. An effective treatment should enhance the antiviral potentials of NK cells and not their immunomodulatory roles. TIM-3 (T-cell immunoglobulin and mucin-containing domain) is a molecule with an essential role in controlling immune tolerance. TIM-3 demonstrated the highest expression among NK cells of patients with chronic liver disorders. Statins have been reported to attenuate the levels of TIM-3 on NK cells.ObjectivesTo investigate the frequencies of NK cells, NKT cells, and TIM-3+ population in patients with CHB upon rosuvastatin (RSV) intervention.MethodsThirty confirmed patients with CHB were randomly assigned into two groups of 15 (receiving 20 mg of RSV or placebo per day) for 12 weeks. We evaluated the percentages of TIM-3+ cells by staining the peripheral blood mononuclear cells (PBMCs) with CD3, CD16, and CD56 markers using flow cytometry.ResultsOur findings indicated that RSV administration could increase CD3- CD56+ NK cells (P>0.05) and CD3+ CD16+ CD56+ NKT cells (P<0.05). RSV intervention could reduce the percentages of TIM-3+ cells among NK cells (P<0.01) and NKT cells (P> 0.05) of patients with CHB compared with the placebo group.ConclusionsThe increased population of NK and NKT cells and the effective reduction of TIM-3+ cells among patients with CHB delineated that rosuvastatin could be proposed as an appropriate modulator of innate immune response (regarding NK and NKT cells) in favor of enhancing their antiviral activities.Keywords: HBV, NK Cells, NKT Cells, Rosuvastatin, Tim-3}
-
Background
As a promising revascularization therapy, percutaneous coronary intervention (PCI) is widely used in patients with coronary artery disease. No-reflow and low thrombolysis in myocardial infarction (TIMI) flow are two adverse periprocedural events.
ObjectivesThis study aimed to compare the effectiveness of atorvastatin and rosuvastatin in reducing the no-reflow phenomenon in patients undergoing primary PCI.
MethodsFollowing a randomized control design, 280 eligible patients with no history of MI or ischemic heart disease (IHD) with ST-elevation myocardial infarction (STEMI) who were candidates for coronary angioplasty underwent angioplasty from May 2020 to December 2020.
ResultsOur results showed that TIMI flow III was significantly higher in the rosuvastatin group, while the no-reflow was not seen in this group (P < 0.001). Also, ST resolution after 90 minutes of PCI was significantly better in the rosuvastatin group.
ConclusionsThis study demonstrated that using a loading dose of rosuvastatin could reduce the no-reflow phenomenon in patients undergoing primary PCI.
Keywords: Angiography, No-reflow, Rosuvastatin, Atorvastatin} -
Background
Rosuvastatin is the newest statin family drug and acts as an HMG-CoA reductase inhibitor. Rosuvastatin can decrease the amount of cholesterol made by the liver and reduce the risk of heart disease. Since liver diseases are one of the significant causes of morbidity and mortality due to drugs toxicity, it is essential to check the liver’s function during widely used drugs such as rosuvastatin. Therefore, this study aimed to investigate the effect of rosuvastatin on the liver in the mature female NMRI mouse strain.
Materials and MethodsIn this experimental study, 30 adult female NMRI strains (mice) at a mean weight of 25-30 grams were divided into five groups control, sham, and treatment groups. The mice of treated groups, including 1, 2, and 3, received rosuvastatin in doses of 10, 20, and 40 mg/Kg of body mass by oral gavage for 21 days. The mice in all groups were dissected after completing the gavage, their hearts were examined, and blood samples were obtained to measure liver enzymes. Then, the mice were sacrificed, and the liver tissue was subjected to antioxidant enzymes. The ELISA test measured the concentrations of the antioxidant and liver enzymes.
ResultsThe results showed that rosuvastatin decreased GPX, MDA, and FRAP with an increase in SOD, AST, and ALT (P<0.05).
ConclusionIt was concluded that high doses of rosuvastatin could damage the liver.
Keywords: Rosuvastatin, Liver, Antioxidant, Statin} -
Background
Statins are the most common drugs used for reducing low-density lipids (LDL). In addition to their lipid-lowering effects, they have well-documented anti-inflammatory actions. The goal of this study was to compare the effects of high dose atorvastatin and rosuvastatin on lipid profiles and high sensitivity C Reactive Protein (hs-CRP) in patients undergoing percutaneous coronary intervention (PCI).
MethodsThe study was done between October 2017 and September 2018 in Semnan Kowsar Hospital. In this randomized trial, 69 patients with atherosclerotic coronary artery disease were randomly assigned 1:1 to receive atorvastatin (80 mg daily) or rosuvastatin (40 mg daily) for 4 months. Levels of hs-CRP and lipid profiles including cholesterol, triglyceride, low-density lipids (LDL), and high-density lipids (HDL) were measured and compared before and after the treatments. Lipid profiles were measured at baseline, 2 months, and 4 months of the treatment.
ResultsSixty patients completed the study. The mean age was 61.1 ± 6.6 years with an excess of males. After 4 months, both drugs could significantly reduce LDL levels, however, the between- group differences were not statistically significant. Rosuvastatin significantly increased HDL levels (p < 0.05). In addition, triglyceride levels had a significant reduction in both groups, yet the differences were not significant. Both drugs caused significant reductions in hs-CRP levels (p < 0.05). Moreover, the effects of treatments were seen in drug naïve patients as well as patients who were on statins prior to the trial.
ConclusionThe results indicate that high dose therapies with atorvastatin and rosuvastatin have similar effects on lipid profiles and hs-CRP levels in patients undergoing PCI.
Keywords: Rosuvastatin, Atherosclerosis, Atorvastatin, Lipid profile, hs-CRP} -
زمینه و هدف
سندرم تونل کارپال شایعترین نوروپاتی عصب مدیان است. شواهدی وجود دارد که استاتین ها ممکن است اثراتی غیر از کاهش کلسترول برای محافظت از اعصاب داشته باشند. این مقاله به بررسی تاثیر روزوواستاتین بر علایم بالینی در بیماران با سندرم تونل کارپال می پردازد.
روش هادر این مطالعه مداخله ای، 50 بیمار با سندرم تونل کارپال خفیف تا متوسط با رضایت آگاهانه در دو گروه درمان و کنترل شرکت کردند. روزانه به مدت یک ماه قرص های روزوواستاتین 20 میلی گرم به گروه درمان و دارونما به گروه کنترل داده شد. مطالعه انتقال عصب بر روی انگشت سوم همه بیماران توسط دو متخصص مغز و اعصاب انجام شد. از مقیاس آنالوگ بصری برای ارزیابی اثر کاهش دهنده درد استفاده شد. به منظور بررسی شدت درگیری عصب میانی بر اساس متد الکترودیاگنوزیس، از اندازه گیری تاخیر هدایت عصب حسی و حرکتی عصب میانی استفاده شد. شدت علایم و وضعیت عملکرد بیماران نیز توسط پرسشنامه بوستون ارزیابی شد.
یافته هانمره درد بیماران در گروه درمان بعد از مداخله 2/69 ± 3/91 کاهش معنی داری نسبت به قبل از مداخله 3/2 ± 5/8 نشان داد (0/025 = p) ولی از نظر شدت علایم و وضعیت عملکرد تفاوت معنی داری وجود نداشت.
نتیجه گیریروزوواستاتین می تواند در کاهش درد همراه با سندرم تونل کارپال موثر باشد. ما بر این باوریم که این کاهش درد می تواند تاثیر قابل قبولی بر کیفیت زندگی بیماران داشته باشد و مشکلات آن ها را کاهش دهد.
کلید واژگان: الکترو دیاگنوزیس, روزوواستاتین, سندرم تونل کارپ, نوروپاتی عصب مدیان}Background and aimsCarpal Tunnel Syndrome (CTS) is the most common neuropathy of the median nerve. There is enough empirical evidence to show that statins may have neuroprotective effect other than cholesterol reduction. In this research we investigated the effect of rosuvastatin on the clinical symptoms in patients with mild to moderate CTS.
MethodsIn this interventional study, 50 patients with mild to moderate CTS participated in both treatment and control groups. Rosuvastatin 20 mg and placebo were administered daily to the treatment and control group respectively. The Nerve conduction study was performed on the third finger of all patients by two neurologists. The Visual Analogue is an acceptable scale to measure the amount of pain that a patient feels. Based on the electrodiagnosis method the neuropathy of the median nerve evaluated by measurements of the sensory and motor nerve conduction delay. The severity of symptoms and performance status of patients were also assessed by the Boston questionnaire.
ResultsThe pain index in the treatment group after intervention was 3.91 ± 2.69 that showed a significant decrease (p = 0.025) compare to before intervention (5.8 ± 3.2), but there was no significant difference in terms of symptom severity and functional status before and after the intervention.
ConclusionRosuvastatin can be effective especially in reducing the pain associated with CTS. We believe this positive effect can have a marked effect on the patients' quality of life and reduce the pain-associated problems.
Keywords: Electrodiagnosis, Rosuvastatin, Carpal tunnel syndrome, Median nerve neuropathy} -
Introduction
Considering the cardioprotective and anti-inflammatory properties of statins, the aim of the present experiment was to investigate the possible involvement of inflammatory cytokines in anti-arrhythmic effects of rosuvastatin in both in vitro and in vivo experiments in rats.
MethodsThree weeks after oral administration of either of rosuvastatin or vehicle, the atria were removed and after incubation with ouabain, time of onset of arrhythmia and asystole were recorded. We also used immunohistochemistry technique to identify the differentially expressed proteins interleukin (IL)-1β, IL-6 and tumor necrosis factor (TNF)-α in atria.
ResultsRosuvastatin significantly postponed the onset of arrhythmia compared to vehicle-treated group. Injection of ouabain increased the atrial expression of IL-1β, IL-6 and TNF-α proteins, while pretreatment of rats with rosuvastatin could significantly attenuate them.
ConclusionOur data suggest that rosuvastatin exerts anti-arrhythmic properties at least in part through modulation of inflammatory cytokines.
Keywords: Rosuvastatin, Cardiovascular, Arrhythmia, Inflammatory cytokines} -
Background and purpose
Bone regeneration can be accelerated by localized delivery of statins. Here, we aimed to evaluate the effect of two thermosensitive hydrogels containing rosuvastatin (RSV) on proliferation and differentiation of human osteoblast-like MG-63 cells.
Experimental approach: Firstly, chitosan (CTS)/glycerophosphate (GP)/gelatin (G) thermosensitive hydrogel was prepared and characterized based on rheological properties, in vitro erosion, and release pattern of RSV and then the optimized mixture was loaded with nanoparticles containing RSV(NRSV). Secondly, the effect of NRSV-embedded in CTS/GP/G on cell viability, alkaline phosphate activity, and cell calcification was evaluated using MG-63 cells and compared with RSV-embedded into hyaluronic acid (HA)/Pluronic® F127 (PF127) hydrogel.Findings / ResultsCTS/GP mixtures with 1 and 1.5 % gelatin existing in solution with low viscosity at 4 °C were solidified at 32-34 °C while the mixture containing 2% gelatin was jellified at room temperature. The gelation times of CTS/GP/G with 1 and 1.5% gelatin were 72 and 44 s, respectively. The hydrogel containing 3% w/v NRSV was also converted to a semisolid upon increasing the temperature to 33-36 °C. Due to the higher gel strength of CTS/GP/G compared to HA/PF127 hydrogel, the release rate of RSV from the NRSV-embedded CTS/GP/G hydrogel was significantly slower than that of HA/PF127 system. As revealed by alkaline phosphatase and mineralization assays, NRSV-embedded in CTS/GP/G hydrogel had the most promotive effect on differentiation of osteoblasts among other mixtures.
Conclusion and implicationNRSV-embedded in CTS/GP/G hydrogel could be efficiently used in the future for bone defects such as osteoporosis and bone fractures.
Keywords: Rosuvastatin, Thermosensitive hydrogel, Tissue engineering} -
The most reported form of statin induced pain is myalgia, conversely peripheral neuropathy is a rare side effect. We report a patient who received rosuvastatin for hypercholesterolemia and experienced episodes of pain in both hands during the night. Rosuvastatin was stopped and atorvastatin was replaced. Re-introduction with another statin resulted in a more severe form of the similar adverse effect after 4 months. This is a rare adverse effect of a extensively prescribed class of drug. Physicians should be aware of the possibility of peripheral neuropathy symptoms in patients on statin therapy.
Keywords: Atorvastatin, Rosuvastatin, Neuropathic Pain, Peripheral Neuropathy} -
Objective(s)
Hypercholesterolemia is a common metabolic disorder in developing and developed countries and is associated with the increased rates of chronic kidney disease (CKD). Statin therapy could reduce cholesterol synthesis as well as progression of CKD. Diversity between statins causes variety in pharmacokinetics and pharmacodynamics and also their pleiotropic effects. In the present investigation we aimed to evaluate the protective potentials of both atorvastatin (Ator) (as lipid-soluble statin) and rosuvastatin (Ros) (as water-soluble statin) against renal histopathological damages in the high cholesterol diet induced hypercholesterolemic rats (HCDIHR).
Materials and MethodsSerum lipid profile, oxidized low density lipoprotein (OX-LDL), malondialdehyde (MDA), urea and creatinine levels, as well as renal histopathology were evaluated.
ResultsWhile Ros acted better than Ator to reduce serum low density lipoprotein cholesterol (LDL-C) (P<0.01), atherogenic index (AI) (P<0.01), MDA (P<0.01), and OX-LDL (P<0.01); no significant differences were noted in their cholesterol (P=0.72), triglyceride (TG) (P=0.79), and very low density lipoprotein cholesterol lowering (VLDL-C) (P=0.79) and high density lipoprotein cholesterol elevating effects (HDL-C) (P=0.72). Ator was more effective to reduce renal histopathologic indices compared to Ros, including accumulation of lipid droplet, glomerular foam cells, mesangial cell proliferation, renal hemorrhage, and tubulointerstitial damages in the kidneys of diet induced hypercholesterolemic rats.
ConclusionThe findings underline that the lipophilic Ator may performs better than Ros in attenuating renal damages in HCDIHR.
Keywords: Atherogenic diet, Atorvastatin, chronic kidney disease, Hypercholesterolemia, Rosuvastatin} -
Statins provide greater protection than predicted from just cholesterol-lowering effects, which is possibly mediated by other pleiotropic actions. This study aimed to examine the possible interaction effect of asthma on lipid profiles and evaluate the effect of rosuvastatin treatment on asthma. The animals were assigned into (1) control, (2) asthmatic, (3) hyperlipidemic, (4) asthmatic-hyperlipidemic, (5) rosuvastatin (40 mg/kg/day intraperitoneally, for 3 weeks)-treated asthmatic, (6) rosuvastatin-treated hyperlipidemic and (7) rosuvastatin-treated asthmatic-hyperlipidemic groups. Tracheal responsiveness to methacholine and ovalbumin, total and differential WBC (white blood cell) counts, and oxidative stress markers in bronchoalveolar lavage fluid (BALF) were evaluated. In the asthmatic and asthmatic-hyperlipidemic groups, tracheal responsiveness to ovalbumin, total WBC count, numbers of eosinophils, neutrophils, and monocytes were higher than the control group (p<0.001). A left-ward shift in the concentration-response curves to methacholine, an increase in nitrite and malondialdehyde concentrations, and a decrease in total thiol content, superoxide dismutase and catalase activities were also observed in the asthmatic and asthmatic-hyperlipidemic groups compared to control group (p<0.01 to p<0.001). Beyond lipid-lowering effect in the treated hyperlipidemic and asthmatic-hyperlipidemic groups, rosuvastatin treatment decreased tracheal responsiveness to methacholine, reduced total WBC count, the numbers of eosinophils, neutrophils, and monocytes, as well as decreased malondialdehyde concentration, and increased total thiol content, superoxide dismutase and catalase activities in treated asthmatic and asthmatic-hyperlipidemic groups (p<0.05 to p<0.001). The improving effect of rosuvastatin on asthmatic and asthmatic-hyperlipidemic animals was shown due to pleiotropic mechanisms including the effect on airway hyperresponsiveness, lung inflammation, and oxidative stress.
Keywords: Asthma, Hyperlipidemia, Oxidative stress, Rosuvastatin} -
BackgroundIt has been shown recently that a considerable burden of pulmonary embolism (PE) roots from an inflammatory response. The activated inflammatory cascade will be responsible for the final fibrotic response of pulmonary vascular bed, creating further mechanical obstruction which results in subsequent right ventricular (RV) dysfunction, influencing functional capacity and future prognosis. Although anticoagulants represent the cornerstone treatment of PE, the drug class has a minimal effect on the mentioned pathology.Study DesignThe present study is a single-center randomized, double-blind, parallel group controlled trial with placebo which will evaluate the effect of high-intensity statin – rosuvastatin 20 mg daily on patients with intermediate-to-high-risk PE. Study population will be selected from patients for whom statin is not otherwise indicated. Primary end point of the present trial will be echocardiographic measures of RV function. We believe that the mentioned indexes represent an accurate surrogate for the functional capacity and prognosis. Our secondary end point will be the composites of PE recurrence and exertional capacity measured by 6-minute walk test.ConclusionsThe result of the present trial might influence the complimentary treatment of acute PE.Keywords: Echocardiography, high-intensity statin, pulmonary embolism, right ventricular function, rosuvastatin}
-
IntroductionAccording to studies, statins possess analgesics and anti-inflammatory properties. In the present study, we examined the antinociceptive, anti-inflammatory and antioxidative effects of rosuvastatin in an experimental model of Chronic Constriction Injury (CCI).MethodsOur study was conducted on four groups; sham, CCI (the control group), CCI+rosuvastatin (i.p. 5 mg/kg), and CCI+rosuvastatin (i.p. 10 mg/kg). We performed heat hyperalgesia, cold and mechanical allodynia tests on the 3rd, 7th, 14th, and 21st after inducing CCI. Blood samples were collected to measure the serum levels of Tumor Necrosis Factor (TNF)-α, and Interleukin (IL)-6. Rats’ spinal cords were also examined to measure tissue concentration of Malondialdehyde (MDA), Superoxide Dismutase (SOD), and Glutathione Peroxidase (GPx) enzymes.ResultsOur findings showed that CCI resulted in significant increase in heat hyperalgesia, cold and mechanical allodynia on the 7th, 14th and 21st day. Rosuvastatin use attenuated the CCI-induced hyperalgesia and allodynia. Rosuvastatin use also resulted in reduction of TNF-α, IL-6, and MDA levels. However, rosuvastatin therapy increased the concentration of SOD and GPx in the CCI+Ros (5 mg/kg) and the CCI+Ros (10 mg/kg) groups compared to the CCI group.ConclusionRosuvastatin attenuated the CCI-induced neuropathic pain and inflammation. Thus, antinociceptive effects of rosuvastatin might be channeled through inhibition of inflammatory biomarkers and antioxidant propertiesKeywords: Rosuvastatin, Neuralgia, Chronic Constriction Injury (CCI), Rats}
-
IntroductionAccording to the powerful antioxidant effects of rosuvastatin, the present study aimed to examine the protective effects of rosuvastatin against oxidative damage of diabetic pancreas by potentiation of the antioxidant capacity in streptozotocin-induced diabetic rats.MethodsExperiment was performed in four groups of male Wistar rats (n=6 in each group): normal, diabetic and two treatment groups (normal and diabetic rats treated with rosuvastatin). Rats were made diabetic by a single intravenous injection of streptozotocin (40 mg/kg) at the beginning of study. Treatment groups received orally rosuvastatin at dose of 10 mg/kg/day. After eight weeks, the pancreas tissues were removed under deep anesthesia. After tissue homogenization, the contents of glutathione and malondialdehyde (MDA) as well as superoxide dismutase (SOD) activity were assessed by biochemical methods.ResultsBlood glucose of diabetic rats was above 350 mg/dl. The MDA content of the homogenized pancreas significantly increased in diabetic rats by 92%. Diabetes also decreased the content of glutathione (32%) as well as SOD activity (68%) of pancreas tissues. Treatment with rosuvastatin noticeably decreased the MDA levels of diabetic pancreas (90%). Moreover, rosuvastatin significantly increased the glutathione content (21%) and SOD activity (67%) of pancreas tissues in treated diabetic rats.ConclusionOur findings reveal that rosuvastatin is able to attenuate the uncontrolled hyperglycemia-induced oxidative damage of pancreas through potentiation of the antioxidant defense system.Keywords: Diabetes mellitus, Rosuvastatin, Hyperglycemia, Oxidative damage, Antioxidant}
-
مقدمهتوانایی ضعیف آنتی اکسیدانی کبد و آسیب اکسیداتیو نقش اساسی در ایجاد آسیب به سلول های کبدی در شرایط دیابت دارد. بر طبق ماهیت آنتی اکسیدانی رزوواستاتین، هدف مطالعه ی حاضر بررسی اثر بهبودی رزوواستاتین بر ظرفیت آنتی اکسیدانی و آسیب اکسیداتیو بافت کبدی در دیابت بود.مواد و روش هابیست و چهار سر موش صحرایی به طور تصادفی در چهار گروه تقسیم شدند (6=n): نرمال، نرمال درمان شده، دیابتی و دیابتی درمان شده. موش ها با یک تزریق داخل وریدی استرپتوزوتوسین به بیماری دیابت مبتلا شدند (40 میلی گرم بر کیلوگرم). حیوانات درمان شده، رزوواستاتین (10 میلی گرم بر کیلوگرم) را به طور روزانه توسط لوله ی گاواژ برای شصت روز دریافت کردند. در پایان، نمونه ی خونی جهت ارزیابی میزان گلوکز و بافت کبدی برای اندازه گیری مالون دی آلدهید، گلوتاتیون و NOx (نیترات و نیتریت) و هم چنین فعالیت آنزیم های کاتالاز و سوپراکسایددیسموتاز جمع آوری شدند.یافته هاالقای دیابت (گلوکز خون>300 میلی گرم در یک صد میلی لیتر) باعث افزایش معنی دار مقدار مالون دی آلدهید (44/0±00/4 میکرومول در لیتر) در مقایسه با گروه نرمال (39/0±08/ 1میکرومول در لیتر) شد، در حالی که رزوواستاتین بدون تاثیر بر گلوکز خون به طور معنی داری (56/0±42/2 میکرومول در لیتر) آن را کاهش داد. دیابت میزان فعالیت آنزیم های کاتالاز و سوپراکسایددیسموتاز را به ترتیب 81 درصد و 54 درصد کاهش داد. درمان با رزوواستاتین باعث افزایش معنی دار فعالیت کاتالاز (90 درصد) و مقدار گلوتاتیون (65 درصد) در موش های دیابتی شد. هم چنین، دیابت به طور معنی داری مقدار NOx (1±15 میکرومول در لیتر) را در مقایسه با گروه نرمال (15±34 میکرومول در لیتر) کاهش داد، در حالی که رزوواستاتین به طور معنی داری آن را افزایش داد (16±61 میکرومول در لیتر).نتیجه گیرینتایج ما نشان می دهد رزوواستاتین قادر است توانایی آنتی اکسیدانی کبد دیابتی را افزایش دهد. بنابراین، درمان با رزوواستاتین ممکن است آسیب های بافتی و اکسیداتیو کبد را در شرایط دیابتی بهبود بخشد.کلید واژگان: رزوواستاتین, دیابت شیرین, ظرفیت آنتی اکسیدانی, آسیب اکسیداتیو, هیپرگلایسمی}IntroductionWeakening of the liver antioxidant capacity and oxidative damage play a crucial role in the genesis of hepatocellular damage during diabetic states. Considering to the antioxidant property of rosuvastatin, the aim of present study was to investigate whether rosuvastatin improves antioxidant capacity and oxidative damage of liver tissue in diabetes.Materials And MethodsTwenty-four rats were randomly divided into four groups (n=6 each), normal, treated normal, diabetic and treated diabetic groups. Diabetes was induced in rats by an intravenous injection of streptozotocin (40 mg/kg). Treated rats received rosuvastatin (10 mg/kg) daily by a gavage tube for sixty days. At the end, blood samples were collected for measuring blood glucose, and liver tissue was removed to determine malondialdehyde, glutathione and NOx (nitrate and nitrite) contents as well as catalase and superoxide dismutase activities.ResultsInduction of diabetes (blood glucose >300 mg/dL) significantly increased the malondialdehyde content (4.00±0.44 µMol/L), compared with the normal group (1.08±0.39 µMol/L), whereas rosuvastatin significantly decreased it (2.42±0.56 µMol/L), without changing blood glucose levels. Diabetes decreased the activities of catalase and superoxide dismutase by 81 and 54%, respectively. Treatment with rosuvastatin increased the catalase activity (90%) and glutathione content (65%) in diabetic rats. Also, diabetes significantly decreased the NOx content (15±1 µMol/L), compared to the normal group (34±15 µMol/L), whereas rosuvastatin significantly increased it (61±16 µMol/L).ConclusionOur results indicate that rosuvastatin can increase the antioxidant capacity of diabetic liver, and treatment with rosuvastatin may hence improve the tissue and oxidative damages of the liver during diabetic states.Keywords: Rosuvastatin, Diabetes Mellitus, Antioxidant capacity, Oxidative damage, Hyperglycemia}
-
زمینه و هدفپرفشاری خون مهم ترین عامل خطر زمینه ساز برای بیماری های قلبی عروقی و تهدیدی جدی محسوب می شود. این مطالعه با هدف تعیین تاثیر مصرف استاتین های موجود در بازار دارویی ایران شامل آتوراستاتین، سیمواستاتین و رزواستاتین بر روی فشارخون خفیف، به انجام رسید.روش بررسیطی این مطالعه کار آزمایی بالینی شاهد دار تصادفی شده 120 بیمار مبتلا به فشارخون خفیف انتخاب شده و به روش تصادفی در 4 گروه 30 نفره توزیع شدند. بیماران گروه اول تا سوم به ترتیب روزانه 20 میلی گرم آتوراستاتین و سیمواستاتین و 10 میلی گرم رزواستاتین به مدت یک ماه دریافت کرده و در گروه چهارم به عنوان گروه شاهد، استاتین تجویز نشد. بیماران 4 گروه در قبل و 1 ماه بعد از شروع درمان، تحت معاینه و بررسی فشارخون با فشارسنج دستی قرار گرفتند. داده های به دست آمده در پایان وارد نرم افزار SPSS شده و با آزمون های کای اسکویر، آنالیز واریانس یک طرفه، T زوجی تجزیه وتحلیل شد.یافته هافشارخون دیاستول در گروه دریافت کننده آنوراستاتین به میزان 3/4±15/68%، در گروه سیمواستاتین به میزان 2/7±7%، در گروه رزواستاتین به میزان 0/3±6/4% و در گروه پلاسبو به میزان 3/4±6/5% کاهش یافته و درصد کاهش فشارخون سیستولی در بین 4 گروه متفاوت بود (0/01P=) و گروه دریافت کننده آتوراستاتین بیشترین کاهش فشارخون سیستولی و دیاستولی را دارا بودند.نتیجه گیریبا توجه به یافته های مذکور و یافته های حاصل از مطالعه می توان نتیجه گیری نمود که مصرف مرتب استاتین می تواند اثر کاهندگی بر روی فشارخون بیماران مبتلا به هایپرتانسیون خفیف داشته باشد.کلید واژگان: فشارخون خفیف, چربی خون بالا, استاتین, آتوراستاتین, رزواستاتین, سیمواستاتین}Background And AimsHypertension is the most important risk factor and a serious threat for cardiovascular diseases. This study was aimed to determine the effect of the statins drugs (included Atrovastatin, simvastatin and Rosuvastatin) in Iranian's population on mild hypertention.MethodsIn a clinical trial, 120 patients with mild hypertension were selected and randomly distributed in four groups of 30 patients. The first group to third received Atrovastatin 20 mg daily and simvastatin 20 mg daily and Rosuvastatin 10 mg daily for one month and as a control group, the fourth group did not receive any statin. Four groups of patients before and 1 month after treatment were examined and their blood pressure was measured manually by sphygmomanometer in Iranian's population with mild hypertention. Finally, data were entered into SPSS software and analyzed using Chi-Square, one-way ANOVA, and paired t-test.ResultsDiastolic blood pressure decreased about 15.68±3.4% in the group receiving Atrovastatin, 7±2.7% in the simvastatin group, 6.4±0.3% in the group receiving Rosuvastatin, and 6.5±3.4% in the placebo group, respectively, while the percentage reduction in systolic blood pressure were different between the four groups (P= 0.01), and the group receiving Atrovastatin showed decreaseing the highest systolic and diastolic blood pressure.ConclusionBased on these findings, it can be concluded that the regular uses of statins may be had lowering effect on blood pressure in patients with mild hypertension.Keywords: Mild hypertension, Hyper lipidemia, Statins, Atrovastatin, Rosuvastatin, Simvastatin}
-
The present work was aimed to develop and characterize rosuvastatin loaded self emulsifying drug delivery system for the effective management of hypolipidemia (RSEDDS) for improving bioavailability, to enhance solubility, to prolong residence time and to provide sufficient amount of drug to a target site in a sustained release manner. Self-emulsifying drug delivery system was prepared by simple emulsification technique, six batches i.e. f1 to f6 were prepared by varying the concentration of oils, surfactant, co-surfactant and co-solvent and evaluated for the various parameters, e.g. optical microscopy, assessment of self emulsification, emulsification time, droplet size analysis, zeta potential measurement, transmission electron microscopy, viscosity determination, drug content, percentage transmittance, in vitro dissolution study and stability studies. The RSEDDS was optimized and batch F5 was opted for further studies. The drug content of selected batch F5 was found to be 97.65 ± 1.37%, which suggests that method for encapsulation was effective. The results of in vitro drug release studies showed about 83% of the drug release within 180 minutes, which exhibit sustained release of drug. There were no significant changes observed in the physical appearance, drug content and in vitro release during stability studies. The studies reveal that the RSEDDS is a potential candidate for sustained release drug delivery which can successfully increase bioavailability.Keywords: Self-emulsifying drug delivery system, rosuvastatin, sustained release, tem, in vitro release}
-
Objective(s)Development of an oral sustained-controlled release vehicle which, slowly releases the drug and maintains an effective drug concentration for a long time is aimed.Materials And MethodsA biodegradable magnetic polymeric drug delivery vehicle, using superparamagnetic iron oxide nanoparticles encapsulating by polyvinylpyrrolidone-block polyethylene glycol-block-poly methacrylic acid (PVP-PEG-PMAA) was developed for targeted and controlled delivery of rosuvastatin. The carrier was characterized by TEM, XRD, and FT-IR techniques.ResultsA typical carrier has about a 9 nm magnetite core, about 20 nm mean diameter with a narrow size distribution. The loading efficiency and pH-controlled release properties of the carrier were examined using a hydrophobic model drug rosuvastatin. Maximum loading efficiency of about 96% and a release amount of 90% of 12 hours were achieved at 37 oC in pH 1.2. While in pH 5.5 and 7.2, release amount of 25% and 37% were obtained respectively.ConclusionThe results indicate that the prepared pH-responsive polymer which covalently coated around magnetic nanoparticles is an efficient carrier with good loading capacity and controlled release property.Keywords: Drug Delivery, Magnetic Nanoparticles, Nano-carrier, pH-responsive polymer, Rosuvastatin}
- نتایج بر اساس تاریخ انتشار مرتب شدهاند.
- کلیدواژه مورد نظر شما تنها در فیلد کلیدواژگان مقالات جستجو شدهاست. به منظور حذف نتایج غیر مرتبط، جستجو تنها در مقالات مجلاتی انجام شده که با مجله ماخذ هم موضوع هستند.
- در صورتی که میخواهید جستجو را در همه موضوعات و با شرایط دیگر تکرار کنید به صفحه جستجوی پیشرفته مجلات مراجعه کنید.